In the 483-person study cited by the regulator, median overall survival was 13.2 months with the combination versus 10.6 months with atezolizumab alone; UK authorisation does not itself establish NHS funding or availability.
MHRA authorises lurbinectedin for extensive-stage small-cell lung cancer
The MHRA granted a UK marketing authorisation for lurbinectedin with atezolizumab as maintenance treatment for eligible adults with extensive-stage small-cell lung cancer.